环维生物

HUANWEI BIOTECH

Great service is our mission

API MONTHLY REPORT IN MAY

The trading volume of the API market in this period is weaker than in the previous period, with the main categories maintaining a low price range, and the market trade channels maintaining low positions or reducing holdings. The sell prices in some regional markets are flexibly adjusted based on actual orders. The transaction prices of Florfenicol, Doxycycline hydrochloride, Tylosin, Neomycin sulfate and other markets were weak, and the supply competition attitude of mainstream factories continued. Pay attention to the recent positive news released by mainstream factories such as Colistin sulfate and Apramycin.

201908261421101467183

1.Macrolide Series:

 

Tylosin Tartrate/ Tilmicosin Phosphate:

Tylosin Tartrate: It has weak terminal demand. 

Tilmicosin Phosphate & Tilmicosin base: Demand is weak, compared with last month, Tilmicosin price continuously went down and keep stable now.

Tiamulin hydrogen famarate: Demand continues to decline and it will take some time to recover.

Erythromycin Thiocyanate:

Some part of the mainstream manufacturers limit production, supply is in shortage, price have little rising, follow-up continuous attention.

Azithromycin: Affected by the upstream raw material supply shortage. Azithromycin factory rise the price, need to increased attention.

 

2.Amido alcohols Series :

Florfenicol: In May, the Florfenicol market is still weak and little dropped. The end users make purchase base on current demands, the price is at bottom level and needs to more attention the manufactures' supplying status.

 

3.Nitrofurans Series :

Furaltadone/Furazolidone: The supplying and production from main makers are stable, and lead time in May.

4.Lincomamides Series :

Lincomycin Hcl: Lincomycin price stable. Some factory adjust little.


Post time: May-19-2023

Leave Your Message: